Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

News Conference News ACC 2025

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

Caitlin E. Cox

April 02, 2025

News Conference News ACC 2025

WARRIOR: No Clear Answers on How to Best Treat INOCA

Yael L. Maxwell

March 29, 2025

News Conference News ACC 2024

Telemedicine Strategy After MI Scores a Win in TELE-ACS

Caitlin E. Cox

April 12, 2024

Presentation ACC 2024

The Effect of Edetate Disodium-based Chelation on Cardiovascular Events in Patients with a Prior Myocardial Infarction and Diabetes – Results of the TACT2 Randomized Trial

Presenter: Gervasio A. Lamas

April 07, 2024

News Conference News ACC 2024

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

Shelley Wood

April 07, 2024

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Shelley Wood

April 06, 2024

News Conference News ACC 2023

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Michael O'Riordan

March 14, 2023

News Conference News ACC 2023

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Michael O'Riordan

March 13, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Conference News ACC 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

Michael O'Riordan

April 12, 2022

News Conference News ACC 2021

For Younger MI Survivors, Stress Boosts Adverse Outcomes

Caitlin E. Cox

May 13, 2021

News Conference News ACC 2021

Prediabetes Linked to Higher MACE Risk

Todd Neale

May 10, 2021

News Conference News ACC 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Yael L. Maxwell

March 30, 2020

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Shelley Wood

March 12, 2018

News Conference News ACC 2018

Inflammatory Bowel Disease May Up the Risk of MI, Especially in Young People

L.A. McKeown

March 09, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

News Conference News ACC 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Michael O'Riordan

March 19, 2017

Advertisement

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

WARRIOR: No Clear Answers on How to Best Treat INOCA

Telemedicine Strategy After MI Scores a Win in TELE-ACS

The Effect of Edetate Disodium-based Chelation on Cardiovascular Events in Patients with a Prior Myocardial Infarction and Diabetes – Results of the TACT2 Randomized Trial

EDTA Chelation No Help in Cutting CV Outcomes After MI in Diabetic Patients: TACT2

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Diabetic Patients in Middle East, Africa Overburdened by ASCVD

Treat to Target or With Intensity? Both Statin Tactics Cut MACE: LODESTAR

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Managing AF Patients Undergoing PCI—Some Lingering Questions

For Younger MI Survivors, Stress Boosts Adverse Outcomes

Prediabetes Linked to Higher MACE Risk

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Inflammatory Bowel Disease May Up the Risk of MI, Especially in Young People

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content